Mucinous breast cancer : clinical characteristics and treatment results in patients treated at the Oncology Centre in Kraków between 1952 and 2002 by Sas-Korczyńska, Beata et al.
Aim of the study: To present the char­
acteristics and clinical outcomes in 94 
patients with mucinous breast cancer 
treated at the Oncology Centre in Kra­
kow between 1952 and 2002.
Material and methods: Stage I or II 
carcinomas were found in 66 patients 
(69.4%) of the presented group and 
in the remaining 28 patients (29.8%) 
stage III disease was diagnosed. In 
27 cases regional lymph nodes were 
involved. All patients had been treat­
ed with surgery: mastectomy (90 pa­
tients) or breast­conserving treatment 
(4 patients). Radiotherapy was admin­
istered in 14 patients, adjuvant chemo­ 
therapy in 14 patients, and endocrine 
therapy in 39 patients.
Results: The maximum follow­up was 
257 months. Ten­year survival was as 
follows: 75.7% (overall survival), 82.5% 
(disease­free survival). During the fol­
low­up, 4 patients developed local re ­ 
currence, 5 patients developed meta­
stases. Second primary cancer was 
found in 8 patients.
Conclusions: The presented results 
confirm the good prognosis in patients 
treated for mucinous breast cancer. 
The diagnosis of early­stage breast can­
cer based on mammography can allow 
breast­conserving treatment.
Key words: mucinous breast cancer, 
mastectomy, breast­conserving treat­
ment, second primary cancer.
Contemp Oncol (Pozn) 2014; 18 (2): 120–123 
DOI: 10.5114/wo.2014.42727
Original paper
Mucinous breast cancer – clinical 
characteristics and treatment 
results in patients treated  
at the Oncology Centre in Kraków 
between 1952 and 2002
Beata Sas-Korczyńska1, Jerzy Mituś2, Andrzej Stelmach2, Janusz Ryś3,  
Anna Majczyk1
1 Clinic of Oncology – Department of Breast and Chest Cancer, Centre of Oncology – 
Maria Sklodowska­Curie Memorial Institute, Krakow Branch, Poland
2 Department of Oncological Surgery, Centre of Oncology – Maria Sklodowska­Curie 
Memorial Institute, Krakow Branch, Poland
3 Department of Tumor Pathology, Centre of Oncology – Maria Sklodowska­Curie 
Memorial Institute, Krakow Branch, Poland
Introduction
Pure mucinous breast cancer represents approximately 1–4% of all malig-
nant breast carcinomas. This type of cancer is most commonly diagnosed in 
women aged 55–60 and above [1–9].
The microscopic assessment of the cancer presents cell clusters floating 
in mucus lakes, separated by thin epithelial membranes containing capillar-
ies. The clusters differ in quantity and in some cases tend to form tubular 
structures. The cancer cells indicate low nuclear atypia. The above character-
istics are dominant in 90% of pure mucinous cancer cases. In mixed form, 
the ductal carcinoma component is present additionally. Mucinous breast 
cancer has been defined as low grade cancer with the presence of hormone 
receptors (oestrogen in 91–94%, progesterone in 79–81%) and lack of HER2 
amplification. Lymph node metastases are rarely seen clinically in this form 
of cancer. All the factors are linked with favourable prognosis [1, 2, 4, 5, 9, 10].
Mucinous breast cancer is usually diagnosed in relatively early stages of 
the disease [2, 6]. In approximately 50% of patients, physical examinations 
indicate the presence of a well-circumscribed tumour in the breast. For the 
remaining 50% of patients, in whom clinical symptoms are not present, the 
form of cancer is diagnosed during screening mammography. Its image re-
sembles benign lesions. In such cases histopathological examinations are 
decisive [5, 11, 12].
In comparison to the infiltrating ductal carcinoma of the breast, pure mu-
cinous breast carcinoma portends a less aggressive clinical course. Ten-year 
disease-free survival rates are over 90% [13–15].
Aim of the study
The purpose of this study is to present the characteristics and the results 
of the treatment of patients suffering from pure mucinous breast carcinoma 
treated over a 50-year period at the Oncology Centre in Kraków.
Material and methods
In the period 1952 to 2002, 94 patients were diagnosed with pure muci-
nous breast carcinoma at the Oncology Centre in Kraków. These cases repre-
sented 0.7% of all (13,571) patients treated for breast cancer in this period.
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Table 1 presents the clinical characteristics of the dis-
cussed group of patients.
The age ranged from 32 up to 85 years and was on av-
erage 64 years (median age: 67). Cancer symptoms (pres-
ence of a tumour in the breast) in 83 patients (88.3%) 
preceded recognition by 1–24 months and lasted for ap-
proximately 6 months. In 11 patients (11.7%) breast cancer 
was recognised by prophylactic exams.
The extent of cancer presented in the study was based 
on the presently adopted TNM classification of breast can-
cer at the time of treatment planning.
The majority of patients (60 patients – 63.8%) were di-
agnosed with stage T2 cancer.
In 67 (71.3%) patients, no lymph node metastases were 
noted. For the remaining 27 patients (28.7%), metastases 
of lymph nodes were indicated: 1–3 lymph nodes in 15 pa-
tients, 4 or more in 12 patients.
Clinical staging was defined as follows: stage I – 15 pa-
tients (16%), stage II – 51 patients (53.4%), stage III – 28 
patients (29.8%).
Table 2 presents the treatment methods.
All the patients suffering from mucinous carcinoma re-
ceived primary surgical treatment. In 90 patients (95.7%) 
a mastectomy was performed, using either Patey’s meth-
od (60 patients) or Halsted’s method (30 patients). In the 
remaining 4 patients (4.3%), breast-conserving treatment 
was introduced (tumour resection and axillary lymphade-
nectomy). In this group of patients post-operative, adju-
vant radiation treatment was provided. Radiotherapy was 
performed in 25 patients (26.6%).
Fourteen patients (14.9%) were treated with adjuvant 
chemotherapy, whereas 39 patients (41.5%) received en-
docrine therapy with tamoxifen.
In the follow-up period the incidence of complications 
and treatment failures was assessed. The presence of sec-
ond primary cancers was also investigated. The 10-year 
overall and disease-fee survival rates were assessed. 
The Kaplan-Meier estimation was used for this purpose.
Results
In the studied group the follow-up lasted a maximum of 
257 months (median: 106 months).
The actuarial 10-year survival rates were as follows: 
overall – 75.7%, disease-free survival – 82.5%.
Figure 1 presents the disease-free survival rates.
In the follow-up period, complications after treatment 
were observed in 15 patients (16%). In 11 patients upper 
limb oedema on the operated side was observed. One pa-
tient (1.1%) suffered from venous thrombosis, 3 patients 
(3.2%) from endometrial hyperplasia of the uterus. All pa-
tients received systemic adjuvant treatment.
Table 3 presents the causes of treatment failures.
In 4 patients (4.3%) local recurrences were noted with-
in 18–43 months (approximately: 33 months) after breast 
cancer treatment.
The development of distant metastases was observed 
in 5 (5.3%). It occurred within 5–169 months (approximate-
ly 77.8 months) after treatment. Metastases were most 
frequently localized in lungs (4 patients).
In 8 patients (8.5%) second primary tumours were not-
ed, among which 3 were localised in the opposite breast. 
The other localisations were: uterus (2 patients), cervix 
(1 patient), lung (1 patient) and non-Hodgkin’s lympho-
ma (1 patient). The above neoplasms developed 24–126 
months (approximately 76 months) after the treatment of 
mucinous breast carcinoma.
Table 1. The clinical characteristics of 94 patients with pure muci­
nous breast cancer treated at the Oncology Centre in Krakow be­
tween 1952 and 2002
Clinical feature No. of patients %
primary tumour in breast (T):
   T1
   T2
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   1–3









Table 2. Treatment methods in 94 patients with pure mucinous 
breast cancer treated at the Oncology Centre in Krakow between 
1952 and 2002
Treatment methods No. of patients %
surgery
   mastectomy
      Patey’s method
      Halsted’s method













endocrine therapy 39 41.5





























Pure mucinous breast cancer has positive prognostic 
features. According to the literature, 5-year and 10-year 
survival rates are: 77–92% and 75–89% (overall), and 76–
91% and 74–93% (disease-free) [2, 4, 12, 16, 17].
The obtained results are comparable to the above. Ten-
year survival rates were: 75.7% (overall) and 82.5% (dis-
ease-free survival).
In approximately 50% of the patients, mucinous breast 
carcinoma is diagnosed by palpation, whereas in asymp-
tomatic cases the cancer is diagnosed after mammograph-
ic screenings [11, 12].
In the studied material, for the majority of patients (83 
from 94 – 88.3%) the main symptom of the cancer was an 
examined tumour in the breast. In the remaining 11.7% of 
the patients the neoplasm was diagnosed in a mammog-
raphy examination. Differences between the studied and 
the previously published data exist due to the fact that 
the studied material comes from a period of 50 years, i.e. 
1952–2002. Over this period diagnosis and treatment rules 
changed due to the development of medicine. This can be 
confirmed by the observations made of the patients suf-
fering from mucinous breast cancer treated at the Oncolo-
gy Centre in Krakow in the 1952–2010 period, presented in 
Table 4. The period 1952–2002 is the subject of the study. 
In more recent years, i.e. in the period 2003–2010, muci-
nous breast carcinoma was detected in mammography 
screenings (34% of patients).
Mucinous breast carcinoma is most often diagnosed in 
older patients, aged 55–60 and above [2–9, 16]. The char-
acteristic feature of this type of cancer is that it can be 
diagnosed in relatively early stages of the disease. A stage 
T1–2 tumour is diagnosed in 93–97% of patients, whereas 
the lack of metastases to lymph nodes is observed in 62-
88% of patients [4, 13, 14, 16–19].
In the studied material stage T1–2 was present in 
74.7% of patients, whereas the lack of metastases to 
lymph nodes (pN0) was observed in 71.3% of patients. 
In case of the presence of metastases to lymph nodes 
16% of patients suffered from metastases of 1–3 lymph 
nodes. According to data from the relevant literature, the 
presence of metastases in 1–3 lymph nodes is diagnosed 
in 10–11% of patients suffering from mucinous breast 
cancer [2, 19].
The results of multivariate analysis presented in the 
literature by Di Saverio et al. and Vo et al. indicate that 
particularly good prognosis in patients suffering from mu-
cinous breast cancer is associated with the following inde-
pendent factors: age, tumour size, status of lymph nodes 
and oestrogen receptor [2, 4, 14]. The significant influence 
of the status of the lymph nodes on the treatment out-
come was indicated in a previous publication published by 
our institute, in which the results of a group of patients 
treated in the years 1952–1979 were presented. The can-
cer-free survival rate drops by two-thirds with recognition 
of the incidence of lymph node metastases (26.7% vs. 
83.3%) [20].
Diab et al. observed convergence between the size of 
the primary tumour and the status of lymph nodes in 
a group of 111 patients with mucinous breast cancer. In the 
case of tumours below 2 cm in size, in 90% of the patients 
metastases to lymph nodes were not indicated. Increase 
in tumour size corresponds with a decrease in the percent-
age of negative lymph nodes, to the extent that in the case 
of tumours over 5 cm in size it equals 56% [2]. As a result, 
the number of performed lymphadenectomies and the ap-
plication of systemic treatment in early mucinous cancer 
deteriorates. The primary method of treatment in patients 
suffering from the studied diagnosis is surgical treatment 
with post-operative adjuvant treatment: radiotherapy, 
chemotherapy, endocrine therapy.
In the presented material 90 out of 94 patients (95.7%) 
were treated with a mastectomy (Patey’s method in 60 pa-
tients, Halsted’s method in 30 patients). In the remaining 
4 patients (4.3%) breast-conserving treatment was intro-
duced.
According to the data from the literature breast-con-
serving treatment is employed in over 60% of patients suf-
fering from mucinous breast cancer [13, 18]. The difference 
with the studied material, in which this procedure involved 
only 4.5% of patients, could reflect the period of the study, 
i.e. 1952–2002. Over this period both the methods and the 
spectra of treatment, along with the indications, changed. 
This conclusion was indicated in a prior publication of the 
Oncology Centre, in which a mastectomy had been per-
formed in all patients [20]. In contrast, Table 4 presents 
Table 3. Failures in 94 patients with pure mucinous breast cancer 
treated at the Oncology Centre in Krakow between 1952 and 2002
Failures No. of patients %
local recurrence 4 4.3
distant metastases
   lung
   bones
   lymph nodes











Table 4. Frequency of breast cancer diagnosis during screening mammography and frequency of breast­conserving surgery in patients with 
pure mucinous breast cancer in material of the Oncology Centre in Krakow
No. of patients Period of therapy
 1952–2002 2003–2010 total
 (present paper)  1952–2010
mucinous breast cancer 94 53 147
diagnosis during screening mammography 11 (11.7%) 18 (34%) 29 (19.7%)
breast-conserving surgery 4 (4.3%) 19 (35.8%) 23 (15.6%)
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a significant increase in the employment of breast-con-
serving treatment in patients with mucinous breast carci-
noma during the years 2003–2010, which was 35.8%.
The data concerning the incidence of radiotherapy indi-
cate that it was performed in 31–90% of patients [4, 13, 14, 
17]. This could be the result of the frequency of breast-con-
serving treatment, during which radiotherapy was an in-
tegral part. In the studied material, in which mastectomy 
was a dominant procedure, 26.6% of patients were treat-
ed with radiotherapy.
According to the literature, the use of adjuvant, system-
ic treatment is comparable with the studied material, with 
frequencies of 10–37% and 14.9% (chemotherapy), and 
33–84% (endocrine therapy) [2, 4, 18, 19].
Vo et al., Li et al. and Bae et al., when comparing various 
histological cancer types, indicated that the involvement 
of systemic treatment in patients with mucinous breast 
cancer is less frequent than in patients with ductal breast 
cancer [4, 13, 17].
In the presented group of patients, 4 out of 94 (4.3%) 
indicated local recurrence, whereas in 5 patients (5.3%) 
the cancer spread. According to the data, local and distant 
failures in patients with mucinous breast cancer are rare 
and concern less than 5% of the patients [4, 18]. Diab et al. 
and Vo et al. claim that the decisive risk factor for the devel-
opment of the failures is the presence of lymph node me-
tastases [2, 4]. Furthermore, as was indicated by Vo et al., 
the failures are less frequently noted in patients with mu-
cinous breast cancer in comparison with other histological 
types of breast cancer [4].
The studied observations and data from the literature 
indicate the good prognosis in case of mucinous breast 
carcinoma. Mammography screenings enable cancer to be 
detected at an early stage, which leaves the possibility of 
introducing breast-conserving treatment.
The authors declare no conflict of interest.
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